These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15847981)

  • 1. The causes and treatment of bone loss associated with carcinoma of the breast.
    Lester J; Dodwell D; McCloskey E; Coleman R
    Cancer Treat Rev; 2005 Apr; 31(2):115-42. PubMed ID: 15847981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of bone loss associated with breast cancer: a review].
    Shao J; Gong YP
    Ai Zheng; 2008 Feb; 27(2):218-22. PubMed ID: 18279626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of osteoporosis after breast cancer.
    Reid DM
    Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
    Hadji P
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):73-82. PubMed ID: 18757208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging bone health issues in women with breast cancer in Hawai'i.
    Carney JF; Davis J
    Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse bone effects during pharmacological breast cancer therapy.
    Bjarnason NH; Hitz M; Jorgensen NR; Vestergaard P
    Acta Oncol; 2008; 47(4):747-54. PubMed ID: 18465344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on identifying and managing osteoporosis in women with breast cancer.
    Yamamoto DS; Viale PH
    Clin J Oncol Nurs; 2009 Oct; 13(5):E18-29. PubMed ID: 19793700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
    Coleman RE; Body JJ; Gralow JR; Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer.
    Limburg CE
    Oncol Nurs Forum; 2007 Jan; 34(1):55-63. PubMed ID: 17562633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
    Camacho PM; Dayal AS; Diaz JL; Nabhan FA; Agarwal M; Norton JG; Robinson PA; Albain KS
    J Clin Oncol; 2008 Nov; 26(33):5380-5. PubMed ID: 18955450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoporosis in breast and prostate cancer survivors.
    Hoff AO; Gagel RF
    Oncology (Williston Park); 2005 Apr; 19(5):651-8. PubMed ID: 15945345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer treatment-induced bone loss.
    Adler RA
    Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):442-5. PubMed ID: 17982349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
    J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
    Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM; Moore TE
    Cancer Nurs; 2008; 31(3):182-90. PubMed ID: 18453874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical management of osteoporosis in women with a history of breast carcinoma.
    Van Poznak C; Sauter NP
    Cancer; 2005 Aug; 104(3):443-56. PubMed ID: 15968687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
    Aapro M
    Breast; 2006 Feb; 15 Suppl 1():S30-40. PubMed ID: 16500238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.